AZ Medical and Educational Goods and Services in Diabetes
AstraZeneca has a deep-rooted heritage and long-standing commitment to the UK, with our global R&D and manufacturing investments. Our relationship with the NHS is at the heart of this and we are proud to support initiatives that enhance patient care or benefit the NHS and maintain patient care in Diabetes.
AstraZeneca offers a medical and educational goods and service in Diabetes to healthcare organisations. Each subject to a stated criteria and avaliable capacity. A number of requirements must be fulfilled for AstraZeneca to provide support to healthcare organisations in these ways, these include:
- MEGS must enhance patient care or benefit the healthcare institution and maintain patient care
- MEGS will not be offered or given as an inducement to prescribe, supply, administer, recommend, buy or sell and AstraZeneca medicine
- MEGS must not be provided to individuals for their personal benefit
The provision of our MEGS is subject to:
- available capacity
- provision being permitted within applicable laws, guidelines and codes (for example the ABPI Code of Practice).
More information is contained within the ABPI Code of Practice
Diabetes Care Dashboard
AstraZeneca is committed to improving person-centred health outcomes for those people living with diabetes. As part of our commitment we have developed a Diabetes Care Dashboard as a service to medicine programme to support health care professionals to enhance care for people living with diabetes, benefitting both patients and the NHS. This service is free of charge.
What is it?
The Dashboard is an informatics-based diagnostic solution that enables GP practices to extract, analyse and review the wealth of primary care held data to assist with practice based self-reflection, and support primary care provider teams to map out the quality of service that they are providing or may wish to aspire to provide in the future.
It is an excel-based analysis and report tool and data extraction is based on an automated extraction query provided by Apollo Medical Systems, which AstraZeneca has commissioned to provide you with the facilities to upload an Excel extract of patient data in a suitable format for the Dashboard.
Patient data does not leave the GP practice and AstraZeneca cannot view any patient personal data. The Dashboard has been designed to signpost healthcare professionals and not to replace clinical decision making following a clinical assessment of a patient.
Who is it for?
This is aimed at individuals who are responsible for improving diabetes care in their CCG, GP Federation, cluster or neighborhood. The Dashboard can be used at an individual practice level by GPs, practice nurses, managers and administrative staff to support quality of care of diabetes at a practice level.
Unfortunately, AstraZeneca is unable to meet all the requests it receives. We focus on the value it brings to patient care and benefit to the NHS and will only consider applications from UK based institutions on a first come, first served basis. The dashboard is also only available for those UK based practices who have access to EMIS and TPP clinical systems. The practice will be required to install Apollo SQL software to enable the extraction of data in order to populate the Diabetes Care Dashboard.
What does it do?
The tool provides the following functionality;
- Enables the extraction of data into reports to assist with the review of national policy such as NICE Guidelines and NICE Quality Standards and delivery of the Quality and Outcomes Framework (QOF)
- Can identify a list of patients who may require a clinical assessment based on their previously recorded clinical test results.
Can AstraZeneca see my practice data or any patient data?
No, AstraZeneca do not see or remove any data from the practice.
Is the dashboard available for anyone?
We focus on the value it brings to patient care and benefit to the NHS and will only consider applications from UK based institutions on a first come, first served basis.
The dashboard is aimed at individuals who are responsible for improving diabetes care in their CCG, GP Federation, cluster or neighbourhood. The dashboard can be used at an individual practice level by GPs, practice nurses, managers and administrative staff to support quality of care of diabetes.It is also only available for those UK based practices who have access to EMIS and TPP clinical systems. The practice will be required to install Apollo SQL software to enable the extraction of data in order to populate the Diabetes Care Dashboard.
Can I share my data with the CCG?
AstraZeneca cannot comment on data sharing policies. Please consult your local policies and relevant teams for data sharing.
Will I have to notify my patients to undertake an audit of their data?
AstraZeneca cannot comment on personal data policies. Please consult your own relevant General Data Protection Regulation (GDPR) policies and any other applicable data protection and privacy legislation to process any Personal Data.
How long will AstraZeneca cover the Apollo licence for?
How many data extractions does this cover?
The agreement covers four data extractions over a one year period.
What data does AstraZeneca hold?
AstraZeneca may retain certain personal data of the Licensee, including but not limited to the name of registered user of the Software, job title, email address and GP Practice name, address and unique identifier.
AstraZeneca will store the name of registered user of the Software, job title and email address solely for the purposes of Software registration, contractual obligation and for the purposes of contacting the GP Practice for any Maintenance Releases or notifications regarding the Software.
AstraZeneca may use the GP Practice name, address and unique identifier in order to map the geographical use of the Software only. AstraZeneca shall not at any time use any personal data collected for any purpose other than those set out in the user agreement and shall not share any personal data with any other third parties without prior written consent.
AstraZeneca will store all Licensee personal data using adequate security measures and will only store such data for the time period required by local laws and AstraZeneca´s internal policies and procedures. When Licensee personal data is no longer necessary for these purposes, the personal data will be securely deleted.
Who do I contact if I am having technical difficulties?
Who is Apollo and why do I need Apollo SQL?
Apollo Data Management Services from Wellbeing Software provide a range of primary care services to extract and scrutinise data in order to apply risk stratification and business intelligence.
Apollo SQL is a data extraction software that will extract data from the GP practice in a consented, appropriate manner to populate the AstraZeneca Diabetes Care Dashboard.
The Diabetes Care Dashboard can only be used with the Apollo SQL data extraction software.
How does this fit in with my local IT governance?
AstraZeneca cannot comment on local IT governance. This is something you will have to discuss with your local IT teams.
Application for the Diabetes Care Dashboard
You have indicated that you are interested in requesting Medical and Educational Goods and Services (MEGS) support from AstraZeneca. In order to help AstraZeneca undertake an assessment of your request and respond to you in a timely manner, please follow the steps below.
- Download and read the AstraZeneca End User Licence Agreement (EULA)
- Download and read the GP Practice Data Consent Form for Apollo SQLSuite & EULA for your reference
- Download the AstraZeneca Diabetes Care Dashboard application form
- Complete the application form and confirm your consent to the AstraZeneca EULA
- Send your completed application to email@example.com
- Your application form will be reviewed and successful applicants will be sent the GP Practice Data Consent Form for Apollo SQLSuite & EULA to read and sign electronically.
Upon receipt of your electronically signed document you will be contacted by Apollo to arrange receipt of the dashboard and to set up Apollo extractions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca on 0800 783 0033.
VVPM ID: GB-25391 Date of Prep: November 2020